BSX

$71.20

Post-MarketAs of Mar 17, 8:00 PM UTC

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$71.20
Potential Downside
44.2%
Whystock Fair Value$39.75
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and tre...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$105.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
36.70
Beta
Defensive asset. Lower volatility than the S&P 500.
0.70
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
12.45%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.90

Recent News

Simply Wall St.
Mar 16, 2026

Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus

Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX) over disclosures about its U.S. Electrophysiology segment. Plaintiffs allege the company misled investors about growth prospects and competitive threats in this business line. The lawsuits follow disappointing financial results and guidance that highlighted pressures in Electrophysiology. Legal claims focus on supposed misrepresentations by company leadership regarding business fundamentals and...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 15, 2026

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement

This medical technology firm delivers advanced noninvasive monitoring and automation solutions to healthcare providers worldwide.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share

RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.

BEARISH
Negative press. News cycle fixated on risk factors or misses.